Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Johns DG, Campeau LC, Banka P, Bautmans A, et al. Circulation 2023;148:144-158.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Johns DG, Campeau LC, Banka P, Bautmans A, et al. Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor. Circulation 2023;148:144-158.
PMID: 37125593